LifeSciences BC > Member Announcements > Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

BURNABY, British Columbia, Nov. 30, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 am Eastern Time (6:00 am Pacific Time) to provide a corporate update and overview of the Company’s poster presentations on two clinical stage epilepsy products, XEN1101 and XEN901, at the 2018 American Epilepsy Society (AES) Meeting.

Dial-In & Webcast Information
To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 5369265. The webcast will be broadcast live on the “Investors” section of Xenon’s website at www.xenon-pharma.com and will be available for replay following the call for 30 days.

About Xenon Pharmaceuticals Inc.

We are a clinical stage, neurology-focused biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our collaborators – a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy, migraine and pain. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com